MenABCWY

BIOLOGICAL6 trials

Sponsors

Novartis Vaccines, GlaxoSmithKline, Pfizer

Conditions

Infections, MeningococcalMeningococcal DiseaseMeningococcal Vaccine

Phase 2

Effectiveness, Immunogenicity and Safety of Meningococcal ABCWY Vaccine Administered to Healthy Adolescents

CompletedNCT02140762

Novartis VaccinesMeningococcal Disease

Start: 2014-05-31End: 2015-02-28Updated: 2018-09-12

Trial to Assess Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Meningococcal ABCWY Vaccine as Compared to Meningococcal B Vaccine in Adolescents

CompletedNCT02212457

GlaxoSmithKlineInfections, Meningococcal

Start: 2014-08-21End: 2016-03-03Updated: 2019-06-27

A Trial to Describe the Safety and Immunogenicity of MenABCWY When Administered on 2 Schedules

CompletedNCT04440176

PfizerMeningococcal Vaccine

Start: 2020-06-17End: 2024-01-05Updated: 2025-01-08

A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants

TerminatedNCT04645966

PfizerMeningococcal Vaccine

Start: 2020-11-26End: 2022-09-15Updated: 2024-03-25

Phase 3

A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.

CompletedNCT03135834

PfizerMeningococcal Vaccine

Start: 2017-04-24End: 2022-10-25Updated: 2023-08-08

MenABCWY Noninferiority Study in Healthy Participants ≥10 to <26 Years of Age

CompletedNCT04440163

PfizerMeningococcal Vaccine

Start: 2020-06-17End: 2022-07-24Updated: 2023-04-18

Related Papers

Randomized trial showing persistence of hSBA titers elicited by a pentavalent meningococcal MenABCWY vaccine for up to 4 years following a primary series and safety and immunogenicity of a booster dose

Vaccine2024-11-083 citations

1638. Development of a Model to Estimate Persistence of hSBA Titers Over Time Following a Primary Series and Booster Dose of the Pentavalent Meningococcal MenABCWY Vaccine

Open Forum Infectious Diseases2023-11-27

Immunogenicity and safety of a pentavalent meningococcal ABCWY vaccine in adolescents and young adults: an observer-blind, active-controlled, randomised trial.

2023-08-1112 citations

Synergistic activity of antibodies in the multicomponent 4CMenB vaccine.

2022-03-1421 citations

Immunogenicity and safety of different schedules of the meningococcal ABCWY vaccine, with assessment of long-term antibody persistence and booster responses – results from two phase 2b randomized trials in adolescents

Human Vaccines & Immunotherapeutics2021-09-2810 citations

6. Pentavalent Meningococcal (MenABCWY) Vaccine is Safe and Well Tolerated With Immunogenicity Noninferior to Coadministered MenB-FHbp and MenACWY-CRM in a Phase 2 Study of Healthy Adolescents and Young Adults

Open Forum Infectious Diseases2020-10-014 citations

7. Two-Dose 4CMenB Vaccination in Adolescents Elicits a Bactericidal Activity against 15 Outbreak-Representative Meningococcal Strains

Open Forum Infectious Diseases2020-10-01

Breadth of coverage against a panel of 110 invasive disease isolates, immunogenicity and safety for 2 and 3 doses of an investigational MenABCWY vaccine in US adolescents - Results from a randomized, controlled, observer-blind phase II study.

2018-07-2723 citations